Showing results (81-90 of 92) with videos related to
Sort By:
Pageof 10
Journal of Clinical Immunology|July 1, 1992
Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature reviewS A Misbah, G P Spickett, P C Ryba, et al.International Journal of Systematic Bacteriology|July 1, 1992
Legionella shakespearei sp. nov., isolated from cooling tower waterU K Verma, D J Brenner, W L Thacker, et al.Cancer Research|January 18, 2011
CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitorsVictoria E Anderson, Michael I Walton, Paul D Eve, et al.British Journal of Cancer|April 15, 2010
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancerG J Rustin, G Shreeves, P D Nathan, et al.Bioorganic & Medicinal Chemistry Letters|June 16, 2005
The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitorsKwai-Ming J Cheung, Thomas P Matthews, Karen James, et al.Molecular Cancer Therapeutics|January 8, 2010
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106Michael I Walton, Paul D Eve, Angela Hayes, et al.Journal of Medicinal Chemistry|November 8, 2013
Aurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cellsVassilios Bavetsias, Amir Faisal, Simon Crumpler, et al.Journal of Medicinal Chemistry|October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitorsMichael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugsMike I Walton, Paul D Eve, Angela Hayes, et al.Oncotarget|August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaMike I Walton, Paul D Eve, Angela Hayes, et al.Pageof 10